The stellar Giuseppe Banna with his stellar mentee Mona Hassan led this magnificent SR and MA - THE DR. A.M.G (ARUNI GHOSE)

oncodaily.com/50883.html

#oncology #cancerresearch #immunotherapy #lungcancer #NSCLC #systematicreview #metaanalysis #clinicaltrials #neoadjuvanttherapy #checkpointinhibitors

Hear best practices for improving outcomes using neoadjuvant, adjuvant & perioperative #immunotherapy approaches for #NSCLC from #LungCancer experts Drs. Patel (Sandip Patel MD), Cascone & Heymach in this new #MedEd video from #TTLC24 bit.ly/48ImRrc

🎥We were delighted to catch up with Clive Peedell on #lungcancer updates at #BTOG24 including whether there is a role for radiotherapy in extensive-stage #SCLC

👉Full interview coming soon to VJOncology.com

BTOG #LCSM #NSCLC #LungCancer

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows.
cancerletter.com/clinical-round…

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the #AACR24 . #NSCLC | Princess Margaret Cancer Centre

targetedonc.com/view/evolving-…

Findings from a phase I trial on personized dendritic cell vaccination for resected #NSCLC 🫁:

✅6 out of 10 patients successfully received the #vaccine with minimal toxicity, leading to systemic T cell responses lasting up to 19 months post-vaccination💉

Single-cell analysis…

A pan-cancer analysis of the microbiome in metastatic cancer - Vivek Subbiah, MD
Antonio Carlos Cell Press

#AACR24 #Cancer #FDA #Fusobacterium #MetastaticCancer #NSCLC #OncoDaily #Oncology #Cancer Research

oncodaily.com/47587.html

Well done Thubeena Manickavasagar on a fab poster from Biomedical Engineering & Imaging Sciences BTOG

discussing validation of radiomics models determining CT parameters predictive of PD-L1 #NSCLC

Some of the amazing work with collaborations between Biomedical Engineering & Imaging Sciences and Guy's and St Thomas' cancer 💪🏻

#BTOG24
Vicky Goh

Learn about a study published in the Journal of Translational Medicine, demonstrating how #spatial data can enable novel observations of several phenotypic immune cell properties associated with ICI therapy's outcome in #nonsmallcelllungcancer ( #NSCLC ). bit.ly/3THEt1d

At #ELCC24 we presented a poster on the phI/II study testing inhaled #cisplatin + systemic chemo-IO for pts with tx-naive stage IV #NSCLC 🫁
A trial conducted by InhaTarget Therapeutics, a spin-off from Université libre de Bruxelles w/ several academic hospitals in #Belgium
Institut Jules Bordet Instituut OncoAlert ESMO - Eur. Oncology

Personalized neoantigen vaccines show promise in early-stage lung cancer, sparking diverse T cell responses, a new study finds:

cell.com/cell-reports-m…

While small, the trial supports feasibility & safety, adding momentum to this precision approach against #NSCLC .…

COPILOT Study Results😱👉: After 2 Years of Pembrolizumab Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)🫁:
🎯Objective Response Rate: 78.6%
🎯Median progression-free survival: 46.1 months
🎯Historical survival at 36 months: 98.2%
🎯Patients had high rates…

Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1<1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up

🔍442 pts (KN-189 and 407), mFU:60.7 mo

✅️mOS: 18.3 vs 11.4 mo (HR:0.64)
✅️5y-OS: 12.5% vs 9.3%

OncoAlert Balazs Halmos
jto.org/article/S1556-…

Meta-analysis of neoadjuv chemoimmunotherapy in #NSCLC :
1. 3 cycles suffice based on pCR, with adjuvant immunotherapy not enhancing EFS.
2. Kudos to JAMA Network Open team, esp. Sara, for elevating paper quality & reviewers' feedback.
3. Special shoutout to the amazing team!

Interesting study! Whether treatment is a segmentectomy, lobectomy, or even SBRT, we need to better understand recurrence in Stage Ia #NSCLC (up to 20% risk) to appropriate treatment & surveillance.
Will AI be the answer?
pubs.rsna.org/doi/10.1148/ra…
#LCSM

Very pleased to present our results on the 1st evidence of the tissue #NanomechanicalSignature as a potent novel tool for the diagnosis and prognosis assessment in pts with #NSCLC at #AACR2024 🚀
It's been a pleasure discussing them with you all!👩🏼‍🔬
Noemi Reguart Jordi Alcaraz UB Hector Sanz, Ph.D.

Wu Y-L et al. have just released the results of a preplanned interim analysis from the ALINA trial -
oncodaily.com/48236.html

#oncodaily #oncology #cancer #NSCLC #ALKpositive #ALINAtrial #alectinib #chemotherapy #clinicaltrial #respiratoryoncology

9th Ed Staging NSCLC; update from Van Schill. T descriptors same. N2 recognition of single station implications. M1c1/2 recognising numbers of organs involved. Great talk. I’m quite excited about this #BTOG24 #LCSM

🚨@Oncoalert KRASKickers New Trial Activation!
This study is for pts with #KRAS G12C adeno #NSCLC (~15% #lungcancer ). Goal is to ⬆️outcomes by early use of #liquidbiopsy to identify who is not responding & transition to sotorasib (KRAS G12C inhibitor).
🫁classic.clinicaltrials.gov/ct2/show/NCT06…

See the updated ASCO living guideline in Journal of Clinical Oncology which provides expert insights into common clinical scenarios encountered when caring for those with advanced #NSCLC 🫁

#OpenAccess article by Dwight Owen, Narjust Florez, MD, FASCO, Erin Schenk, MD, PhD, Jyoti D Patel and colleagues ⬇️